Amblyopia - Epidemiology Forecast - 2036

Key Highlights:

• Amblyopia affects approximately 1-5% of the global population and remains one of the leading causes of monocular visual impairment among children.
• Amblyopia develops when inadequate visual stimulation during early childhood disrupts normal visual pathway maturation, causing the brain to favor input from the stronger eye. This imbalance leads to reduced visual acuity, impaired depth perception, and other visual deficits. Although usually unilateral, rare bilateral cases occur. Common causes include strabismus, anisometropia, and visual deprivation from conditions such as cataract or ptosis.
• Diagnosis typically involves detecting an interocular visual acuity difference of two or more lines despite appropriate refractive correction.
• Amblyopia is considered a diagnosis of exclusion, as it can only be confirmed after excluding all other ocular or cerebral causes of reduced visual acuity. Conditions commonly associated with decreased vision that must be ruled out include refractive errors, cataracts, corneal abnormalities, retinal pathologies, and optic nerve disorders.

DelveInsight's 'Amblyopia - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the Amblyopia, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Amblyopia Understanding and Diagnosis

Amblyopia Overview and Diagnosis

Amblyopia, commonly known as "lazy eye" is a neurodevelopmental visual disorder characterized by reduced best-corrected visual acuity caused by abnormal visual development during early childhood. The condition is most commonly associated with strabismus, anisometropia, refractive error, or visual deprivation, which interfere with normal visual cortex maturation. If left untreated, amblyopia may result in permanent visual impairment persisting into adulthood. It remains one of the leading causes of preventable monocular vision loss in children despite the availability of conventional treatments such as patching, atropine penalization, and corrective lenses.

Diagnosis

Diagnosis of amblyopia is based on a comprehensive ophthalmic examination including assessment of visual acuity, refractive error, binocular vision, and ocular alignment. Cycloplegic refraction is routinely performed, particularly in children, to identify refractive abnormalities such as anisometropia, hyperopia, astigmatism, and myopia. Additional evaluations including cover testing, ocular motility assessment, stereopsis testing, and retinal examination help identify associated conditions such as strabismus or visual deprivation and exclude other ocular causes of reduced vision.

Amblyopia Epidemiology

Key Findings from Amblyopia Epidemiological Analysis and Forecast

• Amblyopia and strabismus are among the leading causes of pediatric visual impairment, with a global prevalence estimated at 1-3.5%.
• The prevalence of amblyopia varies across geographic regions but is consistently reported to be higher in children with family history of visual disorders, premature birth, low birth weight, and developmental ocular abnormalities.
• Japan accounted for approximately 2.2% of the global prevalent amblyopia cases.
• Amblyopia related visual impairment can persist into adulthood when left untreated during childhood, contributing to long-term functional and socioeconomic burden.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of amblyopia, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Amblyopia Patient Population Forecast

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast

FAQs:

• What are the disease risks, burdens, and unmet needs of Amblyopia? What will be the growth opportunities across the 7MM concerning the patient population with Amblyopia?
• What is the Amblyopia prevalence in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• What is the historical and forecasted Amblyopia patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

• Insights on Amblyopia burden and disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
• Clear methodology, validated assumptions, and data-driven rationale to assess the Amblyopia epidemiology analysis and patient population trends.